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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease; the histological spectrum of which ranges from steatosis
to steatohepatitis. Nonalcoholic steatohepatitis (NASH) often leads to cirrhosis and development of hepatocellular
carcinoma. To better understand pathogenesis of NAFLD, we performed the pathway of distinction analysis (PoDA) on a
genome-wide association study dataset of 250 non-Hispanic white female adult patients with NAFLD, who were enrolled in
the NASH Clinical Research Network (CRN) Database Study, to investigate whether biologic process variation measured
through genomic variation of genes within these pathways was related to the development of steatohepatitis or cirrhosis.
Pathways such as Recycling of eIF2:GDP, biosynthesis of steroids, Terpenoid biosynthesis and Cholesterol biosynthesis were
found to be significantly associated with NASH. SNP variants in Terpenoid synthesis, Cholesterol biosynthesis and
biosynthesis of steroids were associated with lobular inflammation and cytologic ballooning while those in Terpenoid
synthesis were also associated with fibrosis and cirrhosis. These were also related to the NAFLD activity score (NAS) which is
derived from the histological severity of steatosis, inflammation and ballooning degeneration. Eukaryotic protein translation
and recycling of eIF2:GDP related SNP variants were associated with ballooning, steatohepatitis and cirrhosis. Il2 signaling
events mediated by PI3K, Mitotic metaphase/anaphase transition, and Prostanoid ligand receptors were also significantly
associated with cirrhosis. Taken together, the results provide evidence for additional ways, beyond the effects of single
SNPs, by which genetic factors might contribute to the susceptibility to develop a particular phenotype of NAFLD and then
progress to cirrhosis. Further studies are warranted to explain potential important genetic roles of these biological
processes in NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) affects almost a third
of the adult population in North America [1]. The clinical-
histologic spectrum of NAFLD ranges from nonalcoholic fatty
liver (NAFL) to nonalcoholic steatohepatitis (NASH) [2]. While
NAFL progresses to cirrhosis in less than 5% of cases, NASH can
progress to cirrhosis in 15–20% of cases [3–4]. NAFLD is also a
risk factor for the development of hepatocellular cancer which can
develop with or without cirrhosis [5]. It is therefore a public health
priority to better understand the pathogenesis of the disease as well
as factors that drive disease progression.
Recently, a single variant in PNPLA (rs738409; I148M) has been
shown to be strongly associated with increased hepatic fat levels,
inflammation and fibrosis [6–7]. Since the discovery of the
association between the PNPLA3 mutation and steatosis and
steatohepatitis, several additional single nucleotide polymorphisms
(SNPs) have been identified to be associated with NASH [7].
However, despite these individual SNP associations, the biologic
mechanisms that distinguish alternative clinical outcomes or
disease progression are largely unknown.
Genetic analysis of biologic processes as opposed to analysis of
individual SNPs may provide more insight into pathogenesis. The
pathway of distinction analysis (PoDA) is a recently developed
computational technique which tests for the association of
variation within multiple genes involved in a defined biologic
pathway with a given phenotype [8]. This method may thus be
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used to investigate whether collections of constitutional genome
variability within biologic processes determine the predisposition
to develop steatohepatitis vs. steatosis or drive the progression to
cirrhosis and hepatocellular cancer. Importantly, it identifies
interactions between SNPs in driving a specific phenotype even
when individually the SNPs may not be significantly related to the
phenotype.
In this analysis, PoDA was performed on a genome wide
association study dataset obtained from the NIDDK NASH
Clinical Research Network (CRN) on 250 highly characterized
adult female subjects with varying phenotypes of NAFLD [9]. The
specific objectives of the study were to determine whether biologic
process variation measured through genomic variation of genes
within these networks was related to the development of
steatohepatitis or cirrhosis. We further evaluated the relationships
of variation within these biological pathways with the severity of
the individual histologic parameters of NAFLD. The results
demonstrate the potential relationship of genomic variability
within key biologic pathways that correlate with both the
individual histologic features of NAFLD, the presence of
steatohepatitis and progression to cirrhosis.
Materials and Methods
The Population Studied
The genome wide association study (GWAS) was conducted on
250 highly characterized adult subjects with varying phenotypes of
NAFLD, a subset of patients who were enrolled into the NAFLD
Database Study of NASH CRN [9]. The database study was an
observational cohort where no therapeutic interventions were
undertaken. From this cohort, non-Hispanic, white, female adults
were selected for the GWAS pilot study in order to reduce
heterogeneity. The median age was 53 years (interquartile range:
46–60 years). The nature and clinical features of subjects in this
cohort have also been published [2,9].
Single SNP association with the phenotype of NAFLD from this
GWAS has already been published [9]. This report represents an
independent analysis of the GWAS dataset to identify genetic
variations in biologic pathways associated with cirrhosis, NASH
and the severity of the individual histologic features of NAFLD.
The underlying assumption for the analysis was that inherited
variations in genes in biologic pathways may determine the
network functional status and thus the disease phenotype. The
NAFLD Database study was approved by the IRB of each of the
participating institutions of the NASH CRN. The GWAS was
approved by the NASH CRN Steering Committee and was
approved by the IRB at Cedars Sinai Medical Center, where the
GWAS was performed. For each subject included in this analysis,
detailed clinical information and data related to the liver histology
was available. The histology was analyzed by the pathology
committee of the NASH CRN and categorized using the NASH
CRN scoring system as described previously [10].
Genotyping
Genotyping was performed with the use of Illumina Hu-
manCNV370-Quadv3 BeadChips as described previously [9].
Eight out of 250 samples were identified as outliers by principal
component analysis (PCA) and were therefore removed with 242
samples remaining for the analysis. Additional filters applied to
SNP data eliminated variants that did not show Hardy-Weinberg
Equilibrium (P,1e-008) and minor allele frequency ,0.02;
resulting in a total of 324,623 SNPs for the analysis.
Data Analysis
The Pathway of Distinction Analysis (PoDA) [8] was applied to
the NAFLD genotype data for the following histologic phenotypes:
steatohepatitis, NAFLD activity score (NAS) and its histologic
components (steatosis, cytologic ballooning and lobular inflamma-
tion), fibrosis stage, and cirrhosis. Each of these phenotypes were
analyzed as qualitative binary traits as described below: (1)
Steatohepatitis: definite steatohepatitis (n = 56) vs. controls (stea-
tohepatitis absent, n = 131). (2) NAS: high score (NAS $5,
n = 114) vs. low scores (NAS ,5, n= 124), Steatosis: moderate to
severe (grades 2–3, n = 102) vs. mild to none (grades ,2, n= 93),
Lobular inflammation: moderate to severe (grades 2–3, n= 96) vs.
mild to none (grades 0–1, n= 99), Ballooning: many ballooned
cells (grade 2, n = 111) vs. controls with no ballooning (grade 0,
n = 84). (3) Fibrosis stage (range 0–4): fibrosis (score $2, n = 130)
and control (score ,2, n= 108). (4) Cirrhosis: cirrhosis (n = 35) vs.
control (n = 204). The total number of samples analyzed is less
than the full sample set because of incomplete clinical data on the
cohort that does not allow a full analysis, and ‘‘n’’ reflects the total
number of subjects on whom the detailed clinical, histological and
GWAS data were available.
To assess the potential impact of population stratification
generating non-disease related associations, the population was
examined for all SNPs included in the analysis. Stratification
analysis was performed on each of 7 phenotypes using Principal
Component Analysis, which was implemented using singular value
decomposition algorithm of R. No evidence of stratification was
found in any of these 7 phenotypes used in the study.
The PoDA analysis was run systematically to the pathways
represented in NCI/Nature Pathway Interaction Database (PID)
[11]. Associations between genes and SNPs were made using
dbSNP build 129. A total of 95924 SNPs in the data could be
associated with at least one of the pathways representing 4849
unique genes. The SNP showing the greatest magnitude of
association with a given phenotype was selected to represent each
gene for a given analysis. A total of 893 pathways were covered in
the dataset with a minimum of 5 genes in each pathway. PoDA
analysis tests for differences in variation between cases and
controls by computing genetic distances based on the variation
observed within and between each group. A distance score was
computed in each pathway for each sample measuring that
sample’s distance to the remaining cases relative to its distance to
the remaining controls for the collection of gene-based SNPs that
constitute a given pathway. The distinction score (DS) quantifying
the differential distributions of distance scores between cases and
controls were then computed for each pathway. Significance
[p(DS)] was assessed by resampling ‘‘dummy’’ pathways of the
same length and computing the fraction of greater DS scores as
described previously [8]. Odds ratios [O.R.] were obtained by
constructing a logistic regression model of case status as a function
of S values which measures the sample’s relative distance from the
remaining ones. P-values were then adjusted for the multiplicity of
pathways using FDR adjustment [q(O.R.)].
Results
The PoDA analysis was performed on the samples and SNPs
that remained following the quality control processing of the
original dataset from 250 subjects (see Materials and Methods for
the details). The collections of SNPs in genes contained in Pathway
Interaction Database (PID) [11] were examined for association
with the following histological features of NAFLD that were
recorded from Central Pathology Review: diagnosis of definite
steatohepatitis, presence of cirrhosis, stage of fibrosis, grade of
Pathways Associated with NAFLD
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Table 1. Pathways significantly associated with NASH diagnosis.
Pathway Source
No. of genes
in pathway
No. of SNPs
in pathway p(DS) O.R. q(O.R.)
Significant
in HCC
Viral Messenger RNA Synthesis Reactome 65 46 0.000 .10 2.51E-06
Recycling of eIF2:GDP Reactome 8 5 0.000 2.58 6.11E-03
mRNA Splicing - Major Pathway Reactome 106 79 0.002 .10 2.63E-07
Elongation of Intron-Containing Transcripts and
co-transcriptional mRNA splicing
Reactome 44 37 0.002 .10 1.11E-05
Cell cycle KEGG 82 64 0.003 .10 8.51E-09
Terpenoid biosynthesis KEGG 6 6 0.003 4.73 4.22E-04
p53 signaling pathway BioCarta 13 12 0.004 .10 3.33E-05
Leading Strand Synthesis Reactome 9 6 0.004 4.50 2.05E-03
inhibition of matrix metalloproteinases BioCarta 8 7 0.006 7.30 2.65E-04
Ethanol is oxidized by NAD+ to form acetaldehyde,
NADH, and H+
Reactome 6 6 0.007 1.88 2.04E-03
cell cycle: g2/m checkpoint BioCarta 23 18 0.009 .10 1.42E-06
regulation of transcriptional activity by pml BioCarta 12 10 0.010 .10 1.25E-05
Cholesterol biosynthesis Reactome 8 8 0.012 .10 4.52E-05
regulation of eif2 BioCarta 11 9 0.013 9.83 1.44E-04
Telomere C-strand (Lagging Strand) Synthesis Reactome 9 6 0.014 4.50 2.05E-03
Folding of actin by CCT/TriC Reactome 10 9 0.015 4.31 5.98E-03
Toll Like Receptor 4 (TLR4) Cascade Reactome 6 6 0.016 3.39 1.58E-03
Lagging Strand Synthesis Reactome 9 6 0.016 4.50 2.05E-03
RNA Polymerase III Transcription Termination Reactome 16 12 0.016 .10 1.53E-05
Mitochondrial tRNA aminoacylation Reactome 21 18 0.017 .10 1.16E-05
Direct p53 effectors NCI-Nature 139 117 0.022 .10 8.51E-09
Pyrimidine biosynthesis (interconversion) Reactome 11 7 0.022 3.50 1.29E-02
Biosynthesis of steroids KEGG 23 21 0.023 .10 8.69E-05
DNA strand elongation Reactome 9 6 0.023 4.50 2.05E-03
Regulation of CDC42 activity NCI-Nature 30 21 0.024 .10 1.18E-06
mitochondrial fatty acid beta-oxidation of unsaturated
fatty acids
Reactome 6 5 0.028 2.00 4.20E-03
Processing of Capped Intron-Containing Pre-mRNA Reactome 35 30 0.028 .10 4.06E-05
Aurora B signaling NCI-Nature 42 36 0.028 .10 8.69E-06
eukaryotic protein translation BioCarta 20 13 0.029 8.75 2.05E-03
O-Glycan biosynthesis KEGG 30 26 0.029 .10 6.89E-08
the prc2 complex sets long-term gene silencing
through modification of histone tails
BioCarta 14 11 0.031 .10 7.00E-05
Bile acid biosynthesis KEGG 31 29 0.032 .10 1.95E-05
Regulation of retinoblastoma protein NCI-Nature 65 57 0.033 .10 1.42E-07
E2F transcription factor network NCI-Nature 72 57 0.033 .10 4.11E-07
Gamma-carboxylation, transport, and amino-terminal cleavage of
proteins
Reactome 8 6 0.034 2.62 9.75E-03 yes
Trafficking of AMPA receptors Reactome 5 5 0.034 1.14 3.41E-01
Phosphorylation of CD3 and TCR zeta chains Reactome 8 5 0.034 4.30 2.02E-04
Antigen processing and presentation KEGG 64 38 0.037 .10 1.22E-05 yes
Hemostasis Reactome 5 5 0.040 .10 2.92E-08
Prostate cancer KEGG 80 67 0.040 3.10 1.28E-03
deregulation of cdk5 in alzheimers disease BioCarta 7 7 0.040 3.72 1.94E-03
Processive synthesis on the C-strand of the telomere Reactome 6 5 0.043 2.57 7.36E-03
Electron Transport Chain Reactome 66 48 0.043 .10 4.67E-06
BARD1 signaling events NCI-Nature 29 27 0.044 .10 1.59E-05
cyclins and cell cycle regulation BioCarta 23 20 0.045 .10 2.84E-05
Pathways Associated with NAFLD
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steatosis, ballooning and inflammation, and the NAFLD activity
score (NAS) which is derived from the grade scores for ballooning,
lobular inflammation, and steatosis. These histological parameters
were either categorized to be absent or present; the severity of
histological features that were scored was analyzed as a binary
score as described in the Materials and methods section.
Biologic Pathways Associated with Definite
Steatohepatitis
Several pathways contained collections of SNPs that when
examined simultaneously within the pathway were significantly
associated with the histologic diagnosis of ‘‘definite steatohepatitis’’
(Table 1). The top two pathways were ‘‘Viral messenger RNA
synthesis’’ and ‘‘Recycling of eIF2:GDP’’ (p(DS) values ,0.001,
and FDR adjusted odds ratio p-values of ,0.01). Several
biosynthesis pathways, such as ‘‘Terpenoid biosynthesis’’, ‘‘Cho-
lesterol biosynthesis’’, ‘‘Pyrimidine biosynthesis’’, ‘‘Biosynthesis of
steroids’’, ‘‘O-Glycan biosynthesis’’, and ‘‘Bile acid biosynthesis’’,
were also significantly associated with the diagnosis of definite
steatohepatitis. The SNP collection in Cell cycle and p53 signaling
pathways were also found to be associated with the diagnosis of
steatohepatitis. The scatter plots of distance scores for two
representative pathways are provided in Figure 1. The gene-based
variations in two pathways previously associated with HCC in a
large Korean cohort [8], ‘‘Gamma-carboxylation, transport, and
amino-terminal cleavage of proteins’’ and ‘‘Antigen processing
and presentation’’, were also associated with the diagnosis of
definite steatohepatitis (p(DS) values = 0.034 and 0.037, respec-
tively, with both showing FDR odds ratio adjusted p-values
,0.01).
Biologic Pathways Associated with Histologic Activity of
NAFLD
We next investigated the relationship between pathway-based
SNPs with NAS, and its independent components: steatosis,
lobular inflammation and ballooning [10]. For this analysis, a NAS
score $5 was used to identify high disease activity. A high NAS
was associated with the SNP variants in ‘‘Glycoprotein hormones’’
Table 1. Cont.
Pathway Source
No. of genes
in pathway
No. of SNPs
in pathway p(DS) O.R. q(O.R.)
Significant
in HCC
1- and 2-Methylnaphthalene degradation KEGG 13 12 0.046 3.70 2.15E-03
Aminoacyl-tRNA biosynthesis KEGG 39 33 0.048 .10 6.02E-06
trefoil factors initiate mucosal healing BioCarta 37 31 0.048 .10 2.37E-06
Nectin adhesion pathway NCI-Nature 28 28 0.049 .10 8.58E-07
Note: Pathway-length based resampled p-values, denoted as p(DS), are given for significant pathways (p,0.05), along with odds ratios and associated FDRs for a logistic
regression model. The pathways previously shown to be associated with HCC are marked.
doi:10.1371/journal.pone.0065982.t001
Figure 1. Two representative significant pathways in steatohepatitis. Scatter plots of distance score S for each pathway and overlayed with
boxplots are given in the left panel; higher values of S indicate the sample is closer to other cases than it is to other controls. Distribution of S for
cases (red) and controls (black) are given to the right. A. ‘‘Viral messenger RNA synthesis’’ – Reactome. B. ‘‘mRNA splicing – Major pathway’’ –
Reactome.
doi:10.1371/journal.pone.0065982.g001
Pathways Associated with NAFLD
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(p(DS) value,0.001, FDR odds ratio adjusted p-value,0.01,
Table S1). Interestingly there were multiple cancer pathways
associated with NAS including ‘‘Colorectal cancer’’
(p(DS) = 0.002, FDR odds ratio adjusted p-value,0.01), ‘‘Renal
cell carcinoma’’ (p(DS) = 0.011, FDR odds ratio adjusted p-
value,0.01), ‘‘Pathways in cancer’’ (p(DS) = 0.021, FDR odds
ratio adjusted p-value,0.01), ‘‘Melanoma’’ (p(DS) = 0.038, FDR
odds ratio adjusted p-value,0.01), and ‘‘Acute myeloid leukemia’’
(p(DS) = 0.043, FDR odds ratio adjusted p-value,0.01). Of note,
these pathways were not shown to be significantly associated with
the diagnosis of definite steatohepatitis. Four pathways ‘‘Vibrio
cholerae infection’’, ‘‘Antigen processing and presentation’’, ‘‘no2-
dependent il-12 pathway in nk cells’’ and ‘‘ErbB signaling
pathway’’ previously described to be associated with HCC were
also associated with a high NAS [8].
The association of individual components of NAS with biologic
pathways using a cutoff of p(DS) value,0.001 was nxt examined.
‘‘Glycoprotein hormones’’ and ‘‘il12 and stat4 dependent signaling
pathway in th1 development’’ were observed to be associated with
steatosis (Table S2). Of the previously described SNP variants in
pathways associated with HCC, only ‘‘growth hormone signaling
pathway’’ was associated with steatosis (p(DS) value = 0.002, FDR
odds ratio adjusted p-value,0.01). ‘‘Hormone ligand-binding
receptors’’ pathway was associated with lobular inflammation
(Table S3) and ‘‘Terpenoid biosynthesis’’ was observed to be
associated with ballooning (Table S4).
Pathways Associated with Advanced Fibrosis and
Cirrhosis
Analysis of fibrosis (stages 3–4 vs.0–2) showed that the top
pathway that was associated with advanced fibrosis was the ‘‘p38
MAPK signaling pathway’’ (p(DS) value,0.001, FDR odds ratio
adjusted p-value,0.01, Table S5). Two pathways ‘‘Galactose
metabolism’’ and ‘‘Reelin signaling pathway’’ associated with
HCC are also associated with fibrosis (p(DS) -values = 0.018 and
0.040 respectively, both with FDR odds ratio adjusted p-values
,0.01).
Extension of this analysis to cirrhosis versus absence of cirrhosis
(Stage 4 fibrosis) identified several pathways that were associated
with cirrhosis (Table 2). Three pathways were observed to be
associated with cirrhosis with a p(DS) value,0.001, FDR odds
ratio adjusted p-value,0.01: ‘‘Il2 signaling events mediated by
PI3K’’, ‘‘Mitotic metaphase/anaphase transition’’, and ‘‘Prota-
noid ligand receptors’’. The scatter plots of distance scores for two
representative pathways are provided in Figure 2. Of note, these
pathways were associated with the presence of cirrhosis but were
not associated to fibrosis alone. The pathways ‘‘lectin induced
complement pathway’’ and ‘‘signaling events mediated by stem
cell factor (c-kit)’’ were also found to be associated with cirrhosis
(p(DS) -values = 0.004 and 0.037, respectively, both with FDR
odds ratio adjusted p-values ,0.01) in previous HCC analysis [8].
Pathways Associated with Multiple Features of NAFLD
NAFLD covers a wide clinical-histologic spectrum, ranging
from steatosis to NASH of varying grades of activity and stages of
fibrosis. To facilitate the identification of components that
contribute to composite phenotypes and to identify common
underlying pathways across different liver histologic manifestations
of NAFLD, the pathways significantly associated with 2 or more
histologic features (p(DS) value,0.05) are listed in Table 3 with
their genes listed in Table S6. Not surprisingly, many pathways
associated with steatosis, lobular inflammation or ballooning was
also observed to be associated with NAS $5. With NAS $5
included, there are 4, 7 and 51 pathways associated with 4, 3 and 2
histological findings/scores respectively. The SNP variants in
‘‘Biosynthesis of steroids’’ and ‘‘Cholesterol biosynthesis’’ are
associated with definite NASH, lobular inflammation, ballooning
and the NAS; ‘‘Eukaryotic protein translation’’ was associated with
Figure 2. Two representative significant pathways in cirrhosis. Scatter plots of distance score S for each pathway and overlayed with
boxplots are given in the left panel; higher values of S indicate the sample is close to other cases than it is to other controls. Distribution of S for cases
(red) and controls (black) are given to the right. A. ‘‘IL2 signaling events mediated by PI3K’’ – NCI-Nature. B. ‘‘Lectin induced complement pathway’’ –
BioCarta.
doi:10.1371/journal.pone.0065982.g002
Pathways Associated with NAFLD
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definite NASH, ballooning, NAS and cirrhosis; ‘‘Terpenoid
biosynthesis’’ was associated with definite NASH, lobular inflam-
mation, ballooning and fibrosis. In addition, ‘‘Antigen processing
and presentation’’ was associated with definite NASH and the
NAS while ‘‘Recycling of eIF2:GDP’’ was associated with definite
NASH, ballooning and cirrhosis.
Discussion
One approach to genetic analysis of complex diseases such as
NAFLD is to stratify the characteristics of histology and identify
the biologic mechanisms underpinning each. While recognizing
that NAFLD represents an interaction between environmental,
Table 2. Pathways significantly associated with Cirrhosis.
Pathway Source
No. of
genes in
pathway
No. of SNPs
in pathway p(DS) O.R. q(O.R.)
Significant in
HCC
IL2 signaling events mediated by PI3K NCI-Nature 37 31 0.000 .10 2.09E-07
Mitotic Metaphase/Anaphase Transition Reactome 8 5 0.000 .10 1.64E-05
Prostanoid ligand receptors Reactome 7 5 0.000 3.17 9.81E-03
Recruitment of NuMA to mitotic centrosomes Reactome 11 11 0.003 .10 8.70E-05
COPI Mediated Transport Reactome 10 10 0.003 .10 4.63E-04
lectin induced complement pathway BioCarta 12 12 0.004 .10 3.84E-06 yes
pertussis toxin-insensitive ccr5 signaling in macrophage BioCarta 9 9 0.005 .10 1.20E-04
granzyme a mediated apoptosis pathway BioCarta 12 9 0.006 6.77 3.53E-04
Synthesis of bile acids and bile salts via 27-hydroxycholesterol Reactome 6 5 0.006 5.50 9.25E-05
PDGFR-alpha signaling pathway NCI-Nature 23 16 0.008 .10 3.75E-06
RNA Polymerase I Promoter Opening Reactome 17 12 0.008 6.21 2.14E-03
Exocytosis of Alpha granule Reactome 41 35 0.010 .10 3.73E-06
Synthesis of bile acids and bile salts Reactome 10 7 0.010 9.15 1.05E-04
EPO signaling pathway NCI-Nature 34 26 0.010 .10 2.30E-06
Regulation of CDC42 activity NCI-Nature 30 21 0.010 .10 7.12E-07
E-cadherin signaling in the nascent adherens junction NCI-Nature 35 33 0.013 .10 9.55E-07
b cell survival pathway BioCarta 13 11 0.015 .10 7.50E-05
Arf6 trafficking events NCI-Nature 40 35 0.017 .10 6.72E-07
Recycling of eIF2:GDP Reactome 8 5 0.018 2.07 3.25E-02
role of mitochondria in apoptotic signaling BioCarta 13 12 0.018 .10 1.43E-04
Effects of Botulinum toxin NCI-Nature 10 9 0.021 .10 2.04E-04
IL2 signaling events mediated by STAT5 NCI-Nature 27 20 0.021 .10 8.10E-07
IL2-mediated signaling events NCI-Nature 55 48 0.023 .10 2.09E-07
HDL-mediated lipid transport Reactome 8 7 0.023 9.22 1.93E-04
Caprolactam degradation KEGG 7 6 0.024 5.43 1.02E-03
eukaryotic protein translation BioCarta 20 13 0.025 9.40 1.23E-03
Glycosphingolipid biosynthesis - lacto and neolacto series KEGG 26 22 0.028 .10 7.59E-06
telomeres telomerase cellular aging and immortality BioCarta 15 14 0.029 .10 5.92E-05
Other semaphorin interactions Reactome 14 12 0.031 .10 8.54E-06
Beta oxidation of hexanoyl-CoA to butanoyl-CoA Reactome 5 5 0.034 1.79 3.21E-02
il22 soluble receptor signaling pathway BioCarta 11 10 0.035 .10 9.10E-04
C21-Steroid hormone metabolism KEGG 10 9 0.035 5.02 6.60E-03
Signaling events mediated by Stem cell factor receptor (c-Kit) NCI-Nature 52 42 0.037 .10 1.31E-06 yes
Beta oxidation of octanoyl-CoA to hexanoyl-CoA Reactome 5 5 0.039 1.81 1.57E-02
Amino acid transport across the plasma membrane Reactome 29 23 0.042 .10 3.73E-06
p38 mapk signaling pathway BioCarta 30 24 0.042 .10 8.18E-06
Nef Mediated CD4 Down-regulation Reactome 7 6 0.044 3.09 6.54E-03
Fatty acid biosynthesis KEGG 6 6 0.046 2.38 3.55E-03
PDGFR-beta signaling pathway NCI-Nature 54 45 0.046 .10 1.99E-07
Internalization of ErbB1 NCI-Nature 34 31 0.047 .10 1.78E-06
Note: Pathway-length based resampled p-values, denoted as p(DS), are given for significant pathways (p,0.05), along with odds ratios and associated FDRs for a logistic
regression model. The pathways previously shown to be associated with HCC are marked.
doi:10.1371/journal.pone.0065982.t002
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Table 3. Pathways significantly associated with 2 or more phenotypes.
pathway (p(DS)
,0.05) Source
No. of genes
in pathway
No. of SNPs
in pathway cirrhosis fibrosis nashdx nas steatosis lobular balloon
Significant
in HCC
No. of
phenotypes
Biosynthesis of
steroids
KEGG 23 21 0 0 yes yes 0 yes yes 0 4
Cholesterol
biosynthesis
Reactome 8 8 0 0 yes yes 0 yes yes 0 4
eukaryotic protein
translation
BioCarta 20 13 yes 0 yes yes 0 0 yes 0 4
Terpenoid
biosynthesis
KEGG 6 6 0 yes yes 0 0 yes yes 0 4
Antigen
processing and
presentation
KEGG 64 38 0 0 yes yes 0 0 0 yes 3
E2F transcription
factor
network
NCI-Nature 72 57 0 0 yes yes 0 0 yes 0 3
Ethanol is oxidized
by
NAD+ to form
acetaldehyde,
NADH, and H+
Reactome 6 6 0 yes yes 0 0 0 yes 0 3
Glycoprotein
hormones
Reactome 8 7 0 0 0 yes yes yes 0 0 3
Hormone ligand-
binding receptors
Reactome 11 10 0 0 0 yes yes yes 0 0 3
Pathogenic
Escherichia
coli infection
KEGG 32 27 0 0 0 yes 0 yes yes 0 3
Recycling of
eIF2:GDP
Reactome 8 5 yes 0 yes 0 0 0 yes 0 3
1- and
2-
Methylnaphthalene
degradation
KEGG 13 12 yes yes 2
3-Chloroacrylic
acid degradation
KEGG 13 13 yes yes 2
angiotensin ii
mediated activation
of jnk pathway via
pyk2 dependent
signaling
BioCarta 34 28 yes yes 2
B cell receptor
signaling
pathway
KEGG 58 47 yes yes 2
BARD1 signaling
events
NCI-Nature 29 27 yes yes 2
Cell cycle KEGG 82 64 yes yes 2
cell cycle: g2/m
checkpoint
BioCarta 23 18 yes yes 2
Cellular roles of
Anthrax toxin
NCI-Nature 22 17 yes yes 2
DNA strand
elongation
Reactome 9 6 yes yes 2
Elongation of
Intron-Containing
Transcripts and
co-transcriptional
mRNA splicing
Reactome 44 37 yes yes 2
ErbB signaling
pathway
KEGG 88 75 yes yes 2
Fatty acid
biosynthesis
KEGG 6 6 yes yes 2
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Table 3. Cont.
pathway (p(DS)
,0.05) Source
No. of genes
in pathway
No. of SNPs
in pathway cirrhosis fibrosis nashdx nas steatosis lobular balloon
Significant
in HCC
No. of
phenotypes
Folding of actin by
CCT/TriC
Reactome 10 9 yes yes 2
Galactose
metabolism
KEGG 26 22 yes yes 2
Gamma-
carboxylation,
transport, and
amino-terminal
cleavage of
proteins
Reactome 8 6 yes yes 2
Gluconeogenesis Reactome 15 11 yes yes 2
growth hormone
signaling pathway
BioCarta 22 18 yes yes 2
inhibition of
matrix
metalloproteinases
BioCarta 8 7 yes yes 2
intrinsic
prothrombin
activation pathway
BioCarta 23 19 yes yes 2
lectin induced
complement
pathway
BioCarta 12 12 yes yes 2
links between
pyk2 and map
kinases
BioCarta 26 22 yes yes 2
mitochondrial
fatty acid beta-
oxidation of
unsaturated fatty
acids
Reactome 6 5 yes yes 2
mRNA Processing Reactome 9 7 yes yes 2
mRNA Splicing -
Major Pathway
Reactome 106 79 yes yes 2
Nef Mediated CD4
Down-regulation
Reactome 7 6 yes yes 2
Neuroactive
ligand-receptor
interaction
KEGG 27 23 yes yes 2
Nicotinate
metabolism
Reactome 12 11 yes yes 2
no2-dependent
il-12 pathway in nk
cells
BioCarta 9 8 yes yes 2
nuclear receptors
coordinate the
activities of
chromatin
remodeling
complexes and
coactivators to
facilitate initiation
of transcription in
carcinoma cells
BioCarta 15 14 yes yes 2
O-Glycan
biosynthesis
KEGG 30 26 yes yes 2
p53 signaling
pathway
BioCarta 13 12 yes yes 2
pertussis toxin-
insensitive ccr5
signaling in
macrophage
BioCarta 9 9 yes yes 2
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behavioral, and genetic factors, genetic analysis permits the
identification of components that are modulated by the genetic
makeup of the individual subject which is largely invariant over
time. Recent GWAS and candidate-gene approaches are examples
of this wherein a number of SNPs such as the PNPLA3 have been
identified that are associated with steatosis, steatohepatitis and
more advanced disease [7,12]. However, in the original publica-
tion from which the data is used for the current study has failed to
identify any relationship between PNPLA3 genetic variability and
NAFLD, which may be a reflection of the modest sample size and
Table 3. Cont.
pathway (p(DS)
,0.05) Source
No. of genes
in pathway
No. of SNPs
in pathway cirrhosis fibrosis nashdx nas steatosis lobular balloon
Significant
in HCC
No. of
phenotypes
Processing of
Capped Intron-
Containing Pre-
mRNA
Reactome 35 30 yes yes 2
Reelin signaling
pathway
NCI-Nature 29 25 yes yes 2
Regulation of
CDC42 activity
NCI-Nature 30 21 yes yes 2
Regulation of
gene expression
in beta cells
Reactome 11 9 yes yes 2
Regulation of
Insulin Secretion
by Glucagon-like
Peptide-1
Reactome 10 9 yes yes 2
Regulation of the
Fanconi anemia
pathway
Reactome 8 7 yes yes 2
regulation of
transcriptional
activity by pml
BioCarta 12 10 yes yes 2
regulators of
bone mineralization
BioCarta 11 9 yes yes 2
rho cell motility
signaling pathway
BioCarta 32 28 yes yes 2
role of nicotinic
acetylcholine
receptors in the
regulation of
apoptosis
BioCarta 17 14 yes yes 2
Signaling events
mediated by Stem
cell factor receptor
(c-Kit)
NCI-Nature 52 42 yes yes 2
Synthesis of bile
acids and bile salts
Reactome 10 7 yes yes 2
Synthesis of bile
acids and bile salts
via 27-
hydroxycholesterol
Reactome 6 5 yes yes 2
Telomere C-strand
(Lagging Strand)
Synthesis
Reactome 9 6 yes yes 2
Trafficking of
AMPA receptors
Reactome 5 5 yes yes 2
trefoil factors
initiate mucosal
healing
BioCarta 37 31 yes yes 2
Vibrio cholerae
infection
KEGG 47 39 yes yes 2
Viral Messenger
RNA Synthesis
Reactome 65 46 yes yes 2
Vitamins Reactome 6 5 yes yes 2
Note: Pathways significantly associated with 2 or more histologic features (p(DS) value ,0.05) are listed along with histologic feature, no. of genes and snps in pathway.
doi:10.1371/journal.pone.0065982.t003
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highly select group of patients (non-Hispanic white female adults)
[9]. In the current study, PNPLA3 exists in the pathway ‘‘1- and 2-
Methylnaphthalene degradation’’, which is significantly associated
with steatohepatitis and ballooning. Importantly, these studies
have been able to de-link the relationship between insulin
resistance and the hepatic histologic ‘‘phenotype’’ of NAFLD,
indicating that genetic factors play an important role in
determining the ultimate disease phenotype and outcomes of
NAFLD.
The analysis performed here extends the genetic analysis
concept by finding biologic pathways whose constitutional
variations have the potential to stratify disease categories,
underpin key subcomponents, and determine alternative clinical
outcomes. Pragmatically, the PoDA method used here accom-
plishes this by incorporating the influence of SNPs that may not be
significantly related to a disease phenotype individually but when
present in combination with other such SNPs within a biologic
network may be determinants of disease phenotype and outcomes
[8]. Our study identifies several novel pathways, and implicitly
gene-based SNPs, that appear to be associated with the presence
and severity of several features of steatohepatitis. These data are
primarily applicable to non-Hispanic white females because of the
sample selection for this pilot GWAS study, therefore the
generalizability of the conclusions remains an open question.
Some of the key pathways linked to the presence of
steatohepatitis and disease progression include those related to
cholesterol synthesis and protein translation. These may be
particularly germane given the central role of the liver in
cholesterol homeostasis and the fundamental importance of
regulation of protein translation to maintain cell viability. NASH
is associated with accumulation of free cholesterol without a
corresponding increase in cholesterol esters [13]. This has recently
been shown to be due to SREBP-2 driven transcriptional
upregulation of HMG CoA reductase the rate-limiting enzyme
for cholesterol synthesis [14]. The upstream components of
cholesterol synthesis are also components of the mevalonate
pathway the only part of the terpenoid synthesis pathway that
exists in humans [15]. Several subcomponents of the terpenoid
pathway and the cholesterol biosynthetic pathway e.g. farnesyl-
and geranyl pyrophosphates affect cell proliferation and apoptosis
[16]. The current studies provide additional evidence that genetic
factors that may modulate the activity of these pathways may
affect activation of cell injury and apoptotic pathways which drive
the development of steatohepatitis.
Another cellular process that has been implicated in the
development of NASH and its progression is the unfolded protein
response (UPR) [17]. Inhibition of protein translation via
phosphorylation of eIF-2a is a key step that relieves endoplasmic
reticulum stress and increased eIF-2a phosphorylation has been
seen in subjects with NASH [17]. Also, numerous microRNAs that
are differentially activated in NASH target eiF-2a [18]. The
identification of the protein translation pathway, of which eIF-2a
is a key component, further corroborates the relevance of the
protein translation machinery in the development of steatohepa-
titis and its progression to cirrhosis. It also indicates that
susceptibility may be attributable to genetic variation within this
pathway. Whether this occurs by altering miRNA expression and
function, eIF structure and function or other mechanisms requires
experimental elucidation.
It is also noteworthy that collections of SNPs in several cancer-
related biological pathways were also identified to be related to
disease activity. These pathways have several overlapping com-
ponents including k-Ras, Wnt-b catenin and multiple kinases
involved in pro-inflammatory and cell proliferative pathways [19–
20]. These findings underscore the importance of the molecular
pathways involved in cell proliferation and inflammation in
defining the histologic activity of NAFLD and the susceptibility
of these pathways to the genetic background of the individual. It is
well known that cirrhosis is a risk factor for hepatocellular cancer
and NASH-related cirrhosis is no exception to that rule [21–22].
Recently, hepatocellular cancer has been identified even in the
absence of cirrhosis in subjects with NAFLD [5]. Our findings
provide a rationale to further investigate the role of genetics in the
development of HCC in such cases.
Conclusion
NAFLD is a complex biological state with multiple histological
phenotypes and varied progression to cirrhosis. While several
genes have been identified to be associated with these phenotypes,
this study identified additional biologic processes whose genetic
variation may underpin alternative phenotypes and determine
outcome. It identifies genetic variation in genes within pathways
that while not significantly related to disease phenotype individ-
ually, in combination are related to the development of
steatohepatitis (the aggressive form of NAFLD), disease activity
as defined by liver histology and its progression to cirrhosis. It also
identifies potential key cellular pathways that may define
genetically susceptible individuals. Several of these pathways are
already closely related to the pathogenesis of NASH and disease
progression. Taken together, the results provide evidence for
additional ways, beyond the effects of single SNPs, by which
genetic factors might contribute to the susceptibility to develop a
particular phenotype of NAFLD and then progress to cirrhosis.
Further studies are warranted to explain potential important
genetic roles of these biological processes in NAFLD.
Supporting Information
Table S1 Pathways significantly associated with NAS.
(PDF)
Table S2 Pathways significantly associated with Stea-
tosis.
(PDF)
Table S3 Pathways significantly associated with Lobu-
lar inflammation.
(PDF)
Table S4 Pathways significantly associated with Bal-
looning.
(PDF)
Table S5 Pathways significantly associated with Fibro-
sis.
(PDF)
Table S6 List of SNP associated genes in pathways.
(XLSX)
Acknowledgments
We thank NASH CRN for allowing us to use the NAFLD GWAS dataset
for this study. We also thank the authors of ‘‘Gastroenterology 139:1567
(2010)’’ for generating the NAFLD GWAS dataset.
Author Contributions
Conceived and designed the experiments: QRC AJS KB. Analyzed the
data: QRC RB YH CY DM. Wrote the paper: QRC AJS KB. Data
interpretation: CY DM EMB.
Pathways Associated with NAFLD
PLOS ONE | www.plosone.org 10 Ju 2013 | Volume 8 | Issue | e659827ly
References
1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al.
(2004) Prevalence of hepatic steatosis in an urban population in the United
States: impact of ethnicity. Hepatology 40: 1387–1395.
2. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A,
et al. (2010) Clinical, laboratory and histological associations in adults with
nonalcoholic fatty liver disease. Hepatology 52: 913–924.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. (2005) The
natural history of nonalcoholic fatty liver disease: a population-based cohort
study. Gastroenterology 129: 113–121.
4. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology 44: 865–873.
5. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. (2009) Hepatocellular
carcinomas in patients with metabolic syndrome often develop without
significant liver fibrosis: a pathological analysis. Hepatology 49: 851–859.
6. Romeo S, Huang-Doran I, Baroni MG, Kotronen A (2010) Unravelling the
pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing
3 protein. Curr Opin Lipidol 21: 247–252.
7. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, et al. (2011)
Genome-wide association analysis identifies variants associated with nonalco-
holic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet
7: e1001324.
8. Braun R, Buetow K (2011) Pathways of distinction analysis: a new technique for
multi-SNP analysis of GWAS data. PLoS Genet 7: e1002101.
9. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, et al. (2010)
Genome-wide association study identifies variants associated with histologic
features of nonalcoholic Fatty liver disease. Gastroenterology 139: 1567–1576,
1576 e1561–1566.
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver
disease. Hepatology 41: 1313–1321.
11. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, et al. (2009) PID: the
Pathway Interaction Database. Nucleic Acids Res 37: D674–679.
12. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, et al. (2009)
A nonsynonymous gene variant in the adiponutrin gene is associated with
nonalcoholic fatty liver disease severity. J Lipid Res 50: 2111–2116.
13. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, et al. (2007) A
lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081–1090.
14. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, et al. (2012) Increased
hepatic synthesis and dysregulation of cholesterol metabolism is associated with
the severity of nonalcoholic fatty liver disease. Cell Metab 15: 665–674.
15. Pollier J, Moses T, Goossens A (2011) Combinatorial biosynthesis in plants: a
(p)review on its potential and future exploitation. Nat Prod Rep 28: 1897–1916.
16. Lane KT, Beese LS (2006) Thematic review series: lipid posttranslational
modifications. Structural biology of protein farnesyltransferase and geranylger-
anyltransferase type I. J Lipid Res 47: 681–699.
17. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, et al. (2008) Activation
and dysregulation of the unfolded protein response in nonalcoholic fatty liver
disease. Gastroenterology 134: 568–576.
18. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, et al. (2008) Nonalcoholic
steatohepatitis is associated with altered hepatic MicroRNA expression.
Hepatology 48: 1810–1820.
19. Tsukamoto H, She H, Hazra S, Cheng J, Wang J (2008) Fat paradox of
steatohepatitis. J Gastroenterol Hepatol 23 Suppl 1: S104–107.
20. Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, et al. (2004)
Retinoic acid receptor alpha dominant negative form causes steatohepatitis and
liver tumors in transgenic mice. Hepatology 40: 366–375.
21. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, et al. (2006)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic
steatohepatitis and hepatitis C. Hepatology 43: 682–689.
22. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. (2010) The
incidence and risk factors of hepatocellular carcinoma in patients with
nonalcoholic steatohepatitis. Hepatology 51: 1972–1978.
Pathways Associated with NAFLD
PLOS ONE | www.plosone.org 11 Ju 2013 | Volume 8 | Issue | e659827ly
